Editorial review: Medriva pages are written by named contributors, reviewed by clinical or subject-matter experts, and updated as evidence or regulatory status changes.

FDA advisers greenlit 6 peptides for compounding

Monday, August 3rd, 2026 - An FDA advisory panel has voted in favor of making six wellness peptides available for pharmacy compounding.

What changed

The source item comes from WCCB Charlotte, which Medriva treats as news discovery. The practical significance is not that readers should change treatment decisions on their own, but that regulatory, safety, access, or development assumptions may need to be checked against current source language.

Why it matters

On July 23 and 24, the PCAC voted by margins ranging from 7–4 to 8–6 to recommend the addition of BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax to the Section 503A Bulk Drug Substances List (503A Bulks List), while voting against Emideltide (also known as delta sleep-inducing peptide, or DSIP). Medriva tracks these items because older summaries can become misleading when supply, enforcement, trial, or safety information changes.

What readers should check

Readers should compare the new source with the relevant Medriva tracker or evergreen page before relying on older assumptions. The item should not be treated as individualized medical advice, a dosing recommendation, or a vendor recommendation.

FDA advisers greenlit 6 peptides for compounding

FDA advisers greenlit 6 peptides for compounding

What changed

Why it matters

What readers should check

Related reading

Find the right peptide page.